All News
The RheumNow Week in Review – Good News for GPA, CZP, Tofa but not ERA (6.1.18)
Dr. Jack Cush reviews this weeks reports from RheumNow.com, including the risk of autoimmunity with vaccination, early RA outcomes, new FDA approvals for certolizumab and tofacitinib and the risk of death from infection with biologics.
Read Article
Ustekinumab: A Novel Intervention in Giant Cell Arteritis
Treatment of refractory giant cell arteritis (GCA) with ustekinumab (Stelara) showed therapeutic promise as a steroid-sparing agent in a small, open-label study, Irish researchers reported.
Read Article
MPO Antibodies Predict Relapses in MPO-ANCA-Associated Vasculitis
A study of MPO-ANCA positive patients followed serially over 2 years shows that reappearance of MPO‐ANCA may predict relapse in patients with MPO‐ANCA positive AAV and that routine MPO‐ANCA monitoring is warranted.
Read Article
The RheumNow Week in Review - Nonadherence and Astronomic Costs (5.11.18)
Dr. Jack Cush reviews highlights, news and journal articles from the past week on RheumNow.com.
Read Article
Mortality Risks Shift in Granulomatosis with Polyangiitis
Mortality remains high in granulomatosis with polyangiitis (GPA), but the causes of death tend to change over time, a researcher reported here.
Read Article
Fixed and Tailored Rituximab Regimens Equal in ANCA Associated Vasculitis
The French Vasculitis Study Group has published the results of the MAINRITSAN2 trial designed to compare individually tailored versus fixed-schedule rituximab (RTX) reinfusion for remission maintenance in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAVs).
Read Article
The RheumNow Week in Review - 23 March 2018
Dr. Jack Cush reviews the highlights from the news, journals and major meetings. New announcements and approval from the FDA; novel associations between ANCA vasculitis and thyroid disease; flare rates after arthroplasty; and pregnancy outcomes for men and women.
Read Article
The RheumNow Week in Review - 16 March 2018
Dr. Jack Cush reviews the highlights from the news, journals and major meetings. Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.
Read Article
The RheumNow Week in Review - 2 March 2018
Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com.
Read Article
Shorter Steroid Courses Effective in ANCA+ Vasculitis
An 8-week course of prednisone plus rituximab (Rituxin) offered good outcomes in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including complete remission, researchers reported.
Read Article
Apremilast Continues to Look Good in Behcet's Disease
The 2018 American Academy of Dermatology Annual Meeting features recent findings of a phase III trial of apremilast in active Behçet’s Disease, showing significant reductions in oral ulcers at week 12 for those treated with apremilast 30 mg twice daily.
Read Article
RWCS Day 3 Podcast
Listen in on the proceedings from the 2018 RWCS meeting in Maui with excerpts from leading teachers in rheumatology. This podcast features topics in dermatology, the fellowship program lead by Dr. Bernie Rubin and videos by the fellows. Featured are Drs.
Read Article
The RWCS - RheumNow Week in Review - 9 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes news and education from the RWCS meeting in Maui.
Read Article
ESRD Death Declines in Vasculitis Patients
In the past 2 decades, mortality from end-stage renal disease (ESRD) among U.S. patients with granulomatosis with polyangiitis (GPA) has declined significantly, a nationwide study found.
Read Article
Higher Fracture Risk with PMR and GCA
Corticosteroid therapy is integral to the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) and a new retrospective cohort study from the UK shows that PMR and GCA have similar, increased risk of fractures.
Read Article
Stroke Risk Highest in the First Year of Lupus (Best of 2017)
Arkema et al has published in Annals of Rheumatic Disease a study showing that ischaemic and haemorrhagic stroke (CVA) is elevated in systemic lupus erythematosus (SLE) compared with the general population, especially in the first year.
Read Article
Advantages of Intravenous Pulse Cyclophosphamide in ANCA-associated Vasculitis
Researchers from the Nottingham University Hospitals have analyzed the efficacy and safety of oral (PO) and intravenous (IV) cyclophosphamide (CTX) in ANCA-associated vasculitis (AAV) patients and demonstrated a trend for fewer relapses, better 1 year survival and less toxicity w
Read Article
The RheumNow Week in Review - 15 December 2017
Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com.
Read Article
FDA Approves Mepolizumab for Churg-Strauss (EGPA)
The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss vasculitis. This is first FDA-approved therapy specifically to treat EGPA.
Read Article
The ACR17 RheumNow Week in Review - 1 December 2017
Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.
Read Article
